Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ:GR) Shares Could Head Skyward as Company is Poised to Become a H

[Image]( Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ:GR) Shares Could Head Skyward as Company is Poised to Become a Huge Player in both the CBD and Medicinal Mushroom Arena! Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ:GR) looks like one of the hottest undetected CBD players around and could soon hit the spotlight as company looks to capitalize on the lucrative Shroom Boom too! CBD has become one of the most talked about topics on Wall Street, in the media, and among consumers. It could become the wellness routine of many Americans and people in the world as more consumers recognize the health benefits of the marijuana compound. The cannabinoid is set to help with anxiety, insomnia, aches and pains, and a long list of other things. A Gallup survey has found that 1 in 7 adults are now using CBD products! 35% of U.S. adults say they are not familiar with it, while another 50% say they are aware of it but do not use it. Do you know what this means? It means there is still a significant chunk of America that could be on its way to using CBD. The market potential is a monster. CBD provides medicinal benefits without the high that comes from THC. Hemp CBD is one of the fastest-growing markets in a generation with sales projected to reach into the billions. The Hemp Business Journal has predicted that the market for CBD will grow from $390 million in 2018 to approximately $1.3 billion by 2022. After cannabis, the next big boom could be psilocybin, or better known as medicinal mushrooms! Many are suddenly asking if shrooms will be the next big thing in plant medicine. Several clinical trials in the last half-decade have concluded that psilocybin can effectively treat anxiety, depression, and other conditions. The federal government is now seriously considering legalizing this natural psychedelic as an adjunct to therapy. Finding the right CBD and psilocybin opportunities on Wall Street could be the ticket to monster profits! Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ:GR) is a company focusing on both and may not be flying under the radar much longer! ___________________________________________________________________ Greetings All, The CBD business is budding and Wall Street is very bullish on the future of CBD. A recent article titled "CBD Market Could Pull In $16 Billion By 2025, Says Study" ran on FORBES website discussing renowned Cowen & Co.'s view of the future revenues for the CBD market. It said: "New York-based investment bank Cowen & Co. released a study on the CBD (cannabidiol) market. Of the findings, one of the most intriguing was that nearly 7 percent of the 2,500 polled, said they had used CBD, an active ingredient in marijuana that purportedly provides relief to patients without getting them high, as a supplement. This figure was far higher than what the Cowen analysts had expected. Yet even more fascinating was the projected estimate Cowen analysts made about the revenue of this market--$16 billion by 2025. The conversation around the psilocybin compound is also getting louder and louder... Leading scientists, academic institutions and government administrations are turning their attention to the benefits of psilocybin as a potential treatment for the global problems of mental health and end of life care! More and more studies are examining the properties of this molecule, and the enormous effects that it can have on the huge global problem of treating mental health. Denver, Colorado voted to decriminalize the drug, and Oakland, California’s city council unanimously concluded that consuming numerous psychedelic plants, mushrooms included, should not be considered criminal. This year Santa Cruz become the latest city to decriminalize "magic mushrooms" and other natural psychedelics, including ayahuasca and peyote. The movement to decriminalize the drug has since picked up steam across the U.S. and Chicago and more cities could be next. CBD is a fast growing lucrative arena already and medicinal mushrooms may be next. Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ:GR) and its wide range of CBD products and entrance into the Mush Rush could catapult current share prices sky high! [( Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ:GR) is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature's Exclusive brands. The company's vision is to become a vertically integrated global CBD brand with a plan to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Low cost production, coupled with international, direct to customer sales channels could provide the foundation for success for the company. Within Europe, Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ:GR)'s Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. The company is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Nature's Exclusive Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ:GR)''s Natures Exclusive brand offers a CBD hemp-oil formulation intended to provide users with the therapeutic benefits that hemp may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. Natures Exclusive offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream, CDB skin serum and CBD coffee. The brand, which provides CBD products to consumers in the US and Europe, clocked up revenue of C$29 million last year! The acquisition of Nature's Exclusive is a milestone for the company and aligns with our goal of becoming a vertically integrated CBD brand. The revenue they generated in 2019 positions us to compete with the largest cannabis companies in the world, and the infrastructure they have in place is a key building block our organization can use to expand further in the [United States] and Europe." -- President Joel Shacker The company has launched a CBD hand sanitizer with 70% ethyl alcohol as its active ingredient, as well as, CBD isolate and Vitamin E. It is initially offered only to consumers in the United States. In order to differentiate the Company's hand sanitizer offering within this crowded space, Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ:GR) has formulated a product that is specifically designed for its target consumers by combining the antimicrobial properties of ethyl alcohol with the benefits of CBD. This ability to formulate and innovate new products of this caliber is a direct result of the Company's strong supply chain, which has continued to operate uninterrupted despite the recent worldwide turmoil. The coronavirus has changed the behavior of many. More people are now actively looking for ways to protect themselves from germs while in public and hand sanitizer has become a staple. The pressing need for hand sanitizer could continue to go on even this is done! According to Research and Markets, hand sanitizer sales are expected to reach more than $3.043 million by the year 2027, which is up from $1.106 million in 2018. This is a projected growth rate of 11.9 percent. "I am very pleased with the continued strength of our new customer acquisition month-to-date as demand remains strong for our CBD and immune products. We anticipate similar demand for our new CBD Hand Sanitizer product due to the limited availability of sanitizer through current retail and eCommerce channels. This product offering will allow us to reach a new client base, while generating significant gross margin and attracting clients to our other product lines." -- Ryan Hoggan, CEO Pure Herbal Immunity Blend Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ:GR) launched the Pure Herbal Immunity Blend under its First Class CBD brand in March of 2020. The all-natural Immunity Blend is made from 100% pure essential oils, including cinnamon leaf, lemon, clove bud, lime, eucalyptus globulus, rosemary, peppermint, spearmint and oregano. Due to customer demand for pure and efficacious products to support the immune system, the Company has also launched an Immune CBD oil, along with an Elderberry Gummy product. The new Immune CBD product contains CBD, B3, B12, Vitamin C and Zinc. Based on the success of the launch, First Class will be increasing marketing efforts throughout the US. Since the launch in March, the company has acquired over 5,500 new customers seeking natural solutions to help support their family’s immune systems. The popularity of the primary product has yielded an average initial order value for immune support customers of $189.00. The Immune Support line is gaining interest from customers that historically were hesitant to purchase CBD, but are now interested in the Immune products and the potential anti-inflammatory benefits of CBD. Many studies agree that CBD can strengthen the immune system. - CBD has anti-inflammatory properties, which can reduce the immune system’s inflammatory response. Inflammation is a vital response that isolates infected areas and prevents toxins from spreading. - CBD can promote apoptosis, or cellular death. - CBD can prevent proliferation, or rapid cellular growth. - CBD can modulate or suppress the function and secretion of cytokines. Cytokines are large groups of proteins, secreted by specific cells in your immune system. Their function is to signal molecules that regulate your body’s immunity, inflammation, and white blood cell production. - CBD can also suppress the production of chemokine, which is a group of cytokines that act as chemoattractants. They lead immune cells to an infection site so that the white blood cells can attack and destroy invading microbes. - CBD can suppress T-cell production and function, ultimately suppressing the immune system’s ability to remember foreign invaders. SOURCE: [( In addition, traditional brick-and-mortar stores have been affected due to social distancing requirements, driving consumers to purchase online from the safety of their homes. “The Immune Support product launch has been the most successful product launch in the history of our First Class brand. E-Commerce is a fast-moving sector, especially during these very unique times we are facing today. Our ability as a company to quickly develop and launch new products to meet market demand is a testament to our expertise. I am very excited by the reception we have received to date for our Immune Line of products. I project demand for the line will continue through Q2 and be a significant driver to our growth for 2020,” -- CEO Ryan Hoggan. Mota Ventures moves forward with the acquisition of Spanish CBD company Sativida Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ:GR) acquired the Sativida brand on March 26, 2020. Sativida is an online retailer in Spain and Mexico, with distribution channels in Spain, Portugal, Austria, Germany, France and the UK. The company is expanding its Sativida brand of CBD products throughout Europe and has said it was “very confident” that it would rapidly acquire customers throughout Europe and the UK. “As the world economy begins to awaken, now is opportune to utilize what we have accomplished in the United States and implement the same strategies in Europe. There are several key market opportunities we have identified in Europe and now is the time to capitalize.” -- CEO Ryan Hoggan CBD is seeing monumental demand in Europe! In Europe alone, the CBD market is on course to grow 400% over the next four years, according to the Brightfield Group. According to New Frontier Data‘s EU CBD Consumer Report: 2019 Overview, 46% of Europeans view CBD favourably, and up to 77% of surveyed respondents also believe CBD should be accessible in some way. THE CBD OPPORTUNITY “The hemp-CBD market alone is estimated to hit $22 billion by 2022.” – The Brightfield Group Boomers and millennials alike are buzzing about three letters - CBD. CBD has become very popular in recent years and is considered one of the hottest new health and wellness trends. It is a natural compound found in cannabis and hemp and does not cause a high like the compound THC. Changes to state and federal laws have led to a rise in the production of CBD-infused products. More and more consumers are realizing the medicinal benefits of this cannabidiol. CBD oil is said to treat a wide variety of health problems, including: pain, epileptic seizures, anxiety disorders and depression, insomnia, stress, skin conditions, etc. According to Grand View Research, by 2027, adult-use medicinal cannabis is expected to become the fastest-growing segment with adult-use products ranging from a highly potent concentrate to a simple food ingredient. Mota Ventures Signs Letter of Intent to Acquire German Leader in Psilocybin Space with a 110,000 Square Foot Manufacturing Facility! Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ:GR) has been aggressively looking to expand its offering into growing segments of the market. Through this process, the company identified psychedelic medicine as a unique opportunity, due to the overwhelming momentum of the sector and the incredible health benefits that can be obtained through derivative products. The Company has come to terms to acquire Verrian, a leading company in the psychedelic medicine sector. THIS IS AN ESTABLISHED EUROPEAN PSYCHEDELIC MEDICINE COMPANY! Verrian owns and operates an EU-GMP, ISO 14001 compliant 110,000 sq. ft. pharmaceutical manufacturing facility in Radebuel, Germany. Verrian purchased the facility from a major global pharmaceutical manufacturer in 2019. Both the facility and equipment are independently appraised at Cdn$10,600,000, including an analytical laboratory, and full pharmaceutical manufacturing suite. Verrian is composed of three distinct business segments: - Pharmaceutical Manufacturing - A portfolio of medical & wellness products - Phyto API - API creation from medical plants - Analytical Testing - European Medicine Agency Standards PRODUCTS FOCUSED ON OPIATE ADDICTION REDUCTION Verrian's singular focus is rewiring the mind to overcome addiction through natural medicine. Specifically, the micro dosing of psilocybin demonstrates potential to remove the dopamine reward of addictive substances, potentially diminishing the desire for addictive substances, thereby reducing or eliminating the need for the addictive substance. The company's product development pipeline is incredibly strong with two products named PSI Gen and PSI Gen+, which are both natural psilocybin extracts from organic mushrooms combined with metabolism-enhancing natural herbs. All of Verrian's compounds are derived from organic, glyphosate free naturally occurring plants, grown specifically for its own purposes While there are many benefits patients may realize from utilizing psychedelic medicine, Verrian is focusing on opioid addiction reduction. This is an important mission as a company as it is estimated that over 13 million people in the world take opioids. For those individuals who have suffered a loss due to one's addiction to a medically prescribed pharmaceutical, this holistic approach provided by Verrian and Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ:GR) is even more meaningful. In addition to treatments for opioids, new studies have demonstrated successful psilocybin treatments for both alcoholism and depression, substantially increasing the market size of potential patients. According to Marketdata, the United States market for alcohol and drug addiction rehab will be worth $42 million in 2020, with over 15,000 private treatment facilities and growing. Verrian's product commercialization process is already underway. The business has invested over C$2 million in clinical trials with two studies that are ongoing. These studies combined with the company's manufacturing abilities will uniquely prepare them to go-to-market once approval is granted. "Our acquisition of Verrian is another step forward in executing our vision to use our powerful eCommerce platform for new and innovative natural health products. While we continue to grow and expand our CBD business units, we will also be ready to fully commercialize the technology created by Verrian. I look forward to working with Verrian's incredibly talented team of clinical researchers and addiction medicine professionals within our existing ecosystem as it will uniquely position us as a leader in psychedelic medicine." "I am extremely excited at the opportunity to acquire an established Psychedelic medicine company in Europe. As an innovative company, Mota always seeks to be a leader in the natural health space and we see the psychedelic medicine market becoming a major part of the industry. This acquisition allows us to have first mover advantage in the Psychedelic market, and Mota's existing distribution network will be ready to capitalize on the opportunity once regulation has been put in place." -- Ryan Hoggan, CEO Mota Ventures Signs Letter of Intent to to evaluate the acquisition of Unified Funding, LLC! Since inception in 2015, Unified has generated a database of over one million customers and has facilitated over C$375,000,000 in consumer transactions. Powered by its proprietary technology platform, Unified has created an eCommerce ecosystem to scale its brands and achieve profitability targets through data analysis, strategic customer acquisition and supply chain management. Founded by partners with more than a decade of eCommerce and technology experience, Unified has rapidly grown into a formidable business focused on aggressive expansion in the natural health products market. The company's diverse platform generates revenue from; licensing, marketing and product fulfillment fees supporting brands in skin care, essential oils, men's health, weight management and CBD including Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ:GR)'s recently audited Nature's Exclusive brand. "A transaction with Unified is another step forward in our expansion as a global eCommerce business. This is the platform and personnel necessary for MOTA to launch and grow brands, such as Nature's Exclusive, which we acquired from Unified in January of 2020." -- Ryan Hoggan, CEO "We have created a very comprehensive eCommerce platform with a team of data analysis, strategic customer acquisition and supply chain management experts that has been proven effective for rapid expansion of natural health brands. We are hopeful that a transaction with Mota will allow our group to use our skills to expand into additional international markets, create new natural health brands and reach more consumers. Mota's access to capital markets to raise growth capital to invest in customer acquisition will give us a distinct advantage to quickly scale, diversify and expand into new high growth product offerings." -- Kevin Keranen, Chairman of Unified. Record Revenues and Monster Subscriber Growth Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ:GR) announced record revenues for the month of April totaling C$3,818,000, representing an increase of 39% compared to April 2019. Expenses totaled C$3,609,000, representing a Gross Profit of C$209,000 for the month. DOMINANT ONLINE CUSTOMER ACQUISITION STRATEGY The Company credits this success to its’ online customer acquisition strategy, which is capitalizing on the strong consumer demand for natural health solutions, resulting in an interim record number of customer acquisitions for the Nature’s Exclusive brand, as well as, new customers for the immune support category introduced in March 2020. The company said it plans to follow a similar rollout strategy as it did in the US market in Europe. For the month of April, Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ:GR) acquired 17,996 new customers. This represents an increase of 48% compared to April 2019. In April, the Company also experienced strong demand from customers enrolling in a subscription, totaling of 14,091 new subscribers during the month. This represents a new subscriber increase of 78% compared to April 2019. Results of the 2019 calendar year audit of the company's Nature's Exclusive brand found: - Revenue of Cdn$29,034,000 - Net income of $3,505,000 - Achieved a margin of over 12% The 2019 financial results for the Nature's Exclusive brand is a strong indicator of the power of the Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ: GR)'s eCommerce business model. This growth continued into 2020. For the months January through April 2020, the Company has generated revenue of C$13,968,000 with related expenses of C$13,514,000. Revenue has increased 188% for this time period over the same period during 2019! The Company's customer acquisition and subscription retention strategies are yielding benefits through the year and into May where the Nature's Exclusive brand has acquired over 17,613 customers from May 1st through May 18th. With over 60% of these customers electing into a subscription, the Company expects reduced costs in the following months, as customer acquisition expense is a one-time cost per customer. The Bottom Line Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ: GR) is trading at mere pennies yet has a narrative that reads like a big board story. The company is poised to take its winning model from America to Europe and looks poised to become a CBD leader on two continents. An entrance into the psilocybin space could be a massive opportunity for the company to capitalize on the Mush Rush. Medicinal mushrooms could be the key to treating depression, anxiety, addiction, and even Alzheimer's Disease. At these share prices Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ: GR) may be a ground-floor situation to keep a close eye on! Mota Ventures Corp. (OTC: PEMTF | CSE: MOTA | (FSE: 1WZ:GR) may be one of 2020's biggest secrets trading on Wall Street headed towards major recognition soon! Sources: [( ttps://www.otcmarkets.com/stock/PEMTF/ [( [( [( [( [( [( [( To get Exclusive Offers make sure you grab your cellphone (which you are probably doing right now) and join our VIP text messaging list (standard text and messaging rates may apply)to make it even easier, if you are on your cell phone now click this Button Below: [SIGN ME UP NOW]( © 2020 PTE.la PTE, LLC (publisher of PTE.la) is NOT registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for PTE, LLC may have long or short positions in securities that may be discussed on this website or newsletter. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are simulated figures from virtual simulated portfolios. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. PTE.la’s sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as are commendation by PTE.la or an offer or solicitation to buy or sell any security. Neither the owner of PTE.la nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with alicensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit . PTE.la makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors. PTE.la is owned and operated by PTE LLC. PTE LLC has been compensated $1,500 One Thousand Five Hundred Dollars cash by Electrik Dojo for a 2 Day marketing program regarding PEMTF (we have not investigated any of the advertisements). Any compensation received by PTE LLC constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. A third party of PTE LLC may have shares and may liquidate, which may negatively affect the stock price. PTE LLC affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. Some of the content in this release contains forward - looking information within the meaning of Section 27 A of the Securities Act of 1 9 9 3 and Section 21 E of the Securities Exchange Act of 1 9 3 4 including statements regarding expected continual growth of the profiled company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward - looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, acompany’s past performance does not guarantee future results. Generally, the information regarding a company profiled is provided from public sources which we believe to be reliable but is not guaranteed by us as being accurate. Further specific financial information, filings and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org. Any investment should be made only after consulting with a qualified investment advisor and reviewing the publicly available financial statement and other information about the company profiled and verifying that the investment is appropriate and suitable. PTE.la makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained in this release or on our website. PTE Team 9 Downing street Newark NJ 07105 USA [Unsubscribe]( | [Change Subscriber Options](